JNJ26854165, with the CAS number 881202-45-5, is a chemical compound that belongs to the class of small molecules and is primarily recognized for its role as a selective inhibitor of certain kinases, particularly in the context of cancer research. This compound has been studied for its potential therapeutic applications, particularly in targeting specific signaling pathways involved in tumor growth and proliferation. Its molecular structure features a complex arrangement that contributes to its biological activity, and it is typically characterized by its solubility in organic solvents and moderate stability under standard laboratory conditions. JNJ26854165 has undergone various preclinical evaluations to assess its efficacy and safety profile, making it a subject of interest in drug development. As with many investigational compounds, its pharmacokinetics, mechanism of action, and potential side effects are critical areas of ongoing research, contributing to the broader understanding of targeted cancer therapies.

JNJ26854165

881202-45-5: JNJ26854165, with the CAS number 881202-45-5, is a chemical compound that belongs to the class of small molecules and is primarily recognized for its role as a selective inhibitor of certain kinases, particularly in the context of cancer research. This compound has been studied for its potential therapeutic applications, particularly in targeting specific signaling pathways involved in tumor growth and proliferation. Its molecular structure features a complex arrangement that contributes to its biological activity, and it is typically characterized by its solubility in organic solvents and moderate stability under standard laboratory conditions. JNJ26854165 has undergone various preclinical evaluations to assess its efficacy and safety profile, making it a subject of interest in drug development. As with many investigational compounds, its pharmacokinetics, mechanism of action, and potential side effects are critical areas of ongoing research, contributing to the broader understanding of targeted cancer therapies.

N1-(2-(1H-Indol-3-Yl)Ethyl)-N4-(Pyridin-4-Yl)Benzene-1,4-Diamine

Serdemetan

<p>Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.</p>

<p>Activates tumor suppressor p53; anti-proliferative in p53 wild-type tumor cells</p>

CAS 881202-45-5

JNJ26854165

N1-(2-(1H-Indol-3-Yl)Ethyl)-N4-(Pyridin-4-Yl)Benzene-1,4-Diamine

Ref: 54-OR1023275

Serdemetan

Ref: 54-BUP09761

Serdemetan

Ref: TM-T2243

JNJ 26854165

Ref: 3D-FI151818